Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 8,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $37.55, for a total value of $300,400.00. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at $394,275. This trade represents a 43.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Pharvaris Stock Up 1.4%

PHVS stock opened at $38.02 on Friday. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -12.47 and a beta of -2.33. The business’s fifty day simple moving average is $35.09 and its two-hundred day simple moving average is $31.38.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Research analysts expect that Pharvaris N.V. will post -3.12 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris in the second quarter valued at about $93,000. Barclays PLC acquired a new stake in Pharvaris in the fourth quarter worth about $77,000. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Pharvaris during the fourth quarter worth about $139,000.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
• Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
• Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PHVS. Leerink Partners raised their target price on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday. UBS Group set a $79.00 price target on Pharvaris in a report on Wednesday. New Street Research set a $60.00 price objective on Pharvaris in a research note on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.50.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.